Current Concepts and Translational Uses of Platelet Rich Plasma Biotechnology by Andia, I. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
Current Concepts and Translational Uses of Platelet Rich
Plasma Biotechnology
I. Andia, E. Rubio-Azpeitia, J.I. Martin and M. Abate
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59954
1. Introduction
A two-decade long research has expedited knowledge about tissue repair mechanisms, and
the field of Regenerative Medicine is gaining ground stimulated by novel insights and the
development of therapeutic biotechnologies, intending to restore tissue architecture and
functionality. Regenerative Medicine technologies concern not only traumatic tissue injuries
but also involve the biological manipulation of pathological conditions aiming to drive tissue
circumstances to normal, i.e. the recovery of tissue homeostasis.
Recent advances in biology and the new understanding of mechanisms such as angiogenesis,
inflammation and main cell activities including proliferation, differentiation and metabolism
have prompted researchers to seek how to manipulate these aspects of tissue and cell biology.
Translation of this knowledge into the development of regenerative medicine technologies is
imperative in order to address the current health care demand markedly boosted by demo‐
graphic changes. Indeed the dramatic increase in the economic and social burden of chronic
and degenerative diseases urges the development of novel therapies.
Biological interventions in Regenerative Medicine fall into four main categories including gene
therapy, tissue engineering, cell-based therapies, and platelet rich plasma (PRP) therapies, with
different success in clinical translation. For example, tissue engineering approaches, i.e. cells
loaded within scaffolds, are in development but still several limitations of 3D tissue constructs
are unresolved; these questions include biocompatibility, improvements in mechanical
properties and/or the size of the 3D constructs [1]. Similarly, the efficacy of different categories
of cell therapies, including mesenchymal stem cells, embryonic stem cells or induced pluri‐
potent stem cells (iPSC), is being tested [2]. However, while registration of new clinical trials
using MSCs derived from the bone marrow or from adipose tissue is growing rapidly
supported by both public and private investments, the iPSC therapies are advancing at a slower
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pace because reprogramming raises serious concerns about safety because of their genetic
instability and potential to form tumors.
PRP, an autologous plasma fraction of peripheral blood, is the simplest regenerative medicine
intervention that is rapidly extending to multiple medical fields mainly due to the easy use
and biosafety that facilitates translation in humans. In fact, regulatory requirements for cell
therapy involve multiple preclinical experiments to demonstrate their safety and non-
teratogen effects in addition to GLP compliance in the preparation, and the use of adequate
expensive installations [3]. In contrast, PRP therapies involve minimal manipulation, and in
general, regulatory requirements are easy to comply thereby facilitating the widespread
clinical use and commercial success of PRP kits and devices. In fact, PRP can be prepared by
using any of the commercial systems available. PRPs can also be prepared by in house
procedures, providing that basic rules of quality are implemented.
While regenerative medicine with cells is directed to inherent non-healing problems and a
wide range of pathological conditions, PRP embrace normal healing conditions such as tissue
repair during surgical invasion or traumatic injuries seeking to enhance and accelerate
physiological repair. Alternatively, PRPs as occurs with cell therapies, seek to direct non-
healing conditions, e.g. chronic conditions such as osteoarthritis (OA) or tendinopathy,
towards healing and restoration of tissue homeostasis.
Due to the biosafety of these products, i.e. advantageous balance risk-benefit, clinical appli‐
cations have preceded the basic research. Actually, in its very beginnings PRPs have been used
with a vague idea of the biological mechanisms they were influencing. Thereafter, most studies
were directed to examining clinical outcomes rather than identifying the precise biochemical
mechanisms underlying PRP effects, which remain to be elucidated in the most part. In fact,
PRP widespread use was not driven by the principles of the scientific methods instead patient
demand has been boosted by sports news and propaganda reporting that outstanding elite
athletes had been successfully treated with PRP. The need is clear, to investigate and describe
main PRP targets and action mechanisms underlying their clinical effects. In fact, translational
medicine addresses both, the biological and the clinical aspect of the novel biotechnologies.
In this book chapter, first, we will discuss recent progress on understanding the tissue
regeneration process with a particular focus on the healing stages, and the role of PRP released
signaling proteins in targeting different cells and inducing paracrine actions. Current biolog‐
ical interventions aiming tissue regeneration stem from two concepts, namely cells responsible
for tissue homeostasis, and the signaling cytokines that control cell fate. Several cell pheno‐
types are involved in tissue repair and some processes such as inflammation and angiogenesis
are commonly involved in the repair process in several conditions. Hence, several notions of
tissue repair mechanisms are compatible with the biological hallmarks of regeneration in
different tissues. Common mechanisms involved in healing can be modulated using PRP. This
is the basic knowledge to drive clinical applications.
Second, from a practical point of view on PRP biotechnology we will discuss the main
formulations, and summarize commercial systems to prepare PRP. Regulatory requirements
will be briefly exposed.
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Lastly, we will focus on translational uses, that is to say current PRP interventions from the
clinical investigation perspective. We will summarize PRP applications in surgery with special
emphasis in novel developments, the current use of PRP in ulcers, ophthalmology and
dermatology, as well as foremost conservative treatments in orthopedics and sports medicine.
We will discuss main obstacles for the advancement of PRP science and future perspectives.
2. Tissue repair and regeneration
Despite growing knowledge on tissue regeneration mechanisms currently we are incapable to
fully regenerate human tissues. The only approximation to tissue regeneration in the human
body is the so-called “compensatory regeneration” in the liver. In fact, after lobe removal the
liver compensates the loss and recovers its former size by balanced proliferation of all the
existing cell types, including hepatocytes, kupffer macrophages, endothelial cells, duct cells,
and fat storing cells. Moreover, these cells retain their functional identity and are able to
produce all the liver-specific enzymes necessary for liver function [4].
In contrast to the lack of regenerative mechanisms in humans where there is no return to the
embryonic state and no recapitulation of differentiating mechanisms, some amphibians as the
salamander, after amputation replace their body parts by recapitulating embryological events.
In these amphibians regeneration involves reactivation of developmental mechanisms in the
post-natal life to restore wounded tissues identically as they were before injury.
Research in this area of experimental biology has provided useful information to the field of
Regenerative Medicine. For example, the study of amphibians offers important insights into
the mechanisms involved in the regeneration of complex structures. Indeed, after limb
amputation in the salamander, a mass of undifferentiated cells called blastema is formed, and
the blastema is capable of growing into different body parts [5].
Nevertheless, dramatic differences between frogs and salamanders in tissue repair/regenera‐
tion exist. Indeed adult frogs, despite being amphibians, cannot recapitulate embryologic
mechanisms in their adult life. These differences are mainly attributed to at least three broad
dissimilarities, first in their immune systems, secondly in cell differentiation mechanisms, and
lastly in their potential for nerve regeneration [6].
Therefore these three notions derived from studies on experimental biology will drive our
exposition of potential layers of PRP control in healing mechanisms. We will focus firstly, on
immune-modulatory mechanisms i.e. the pattern of leukocyte infiltration (PMNs, monocytes,
lymphocytes), and macrophage polarization, second the importance of stem/progenitor cell
activation, and adequate differentiation, and third the requirement of nerve participation, as
regeneration is dependent on the presence of nerves. In fact a minimum number of nerve fibers
is necessary for regeneration to take place. We will emphasize the importance of an adequate
crosstalk between immune cells, progenitor cells as well as local differentiated cells and the
paracrine actions.
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All these regenerative events constitute different layers of biological control that can be
influenced by PRP administration.
Figure 1. Potential layers for PRP influence in tissue regeneration
3. Outlook for the control of tissue healing using PRP
3.1. Inflammation
3.1.1. Cell death and DAMPs in the extracellular space
Injury in multicellular organisms is accompanied by cell damage and death, proportional to
the magnitude of tissue injury that triggers a sophisticated sequence of reactions to cope with
the insult. The degree of the inflammatory response depends on the severity of the injury that
can induce different magnitudes of cell damage and death. Loss of cell integrity activates innate
immune sensors by releasing to the extracellular space a myriad of intra-cytoplasmic mole‐
cules, known as DAMPs (Danger Activating Molecular Patterns). Among the DAMPs released
by dying cells there is a growing list including cytosolic and nuclear proteins such as high
mobility group box 1 (HMGB1), alarmins such as S100, and non-proteins including uric acid,
DNA, RNA, and ATP. The inflammatory response triggered by the detection of DAMPs is an
evolutionary conserved mechanism present in both vertebrates and invertebrates.
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DAMPs transmit stress signals to the organism, and stimulate innate immune responses,
starting by leukocyte infiltration, following by macrophage polarization and closing with the
resolution of inflammation. This set of mechanisms is known as the inflammatory response,
and serves to minimize the insult, and repair the damaged tissue in doing so contributes to
the recovery of tissue homeostasis.
Cell death can result from injury but can also occur physiologically as a component of tissue
homeostasis, since all tissues in accordance with their physiologic turnover rate replace old
cells by new ones. In tissue turnover cell death is not accompanied by any inflammatory
reaction, probably because DAMPs in the extracellular space do not reach a threshold con‐
centration. Importantly, errors in the control of immune homeostasis may be behind chronic
diseases.
The administration of PRP during this phase can rescue damaged cells as PRP contains
cytokines that can promote cell survival, as shown both in vivo and in vitro. For example,
during cell auto-transplantation for the treatment of tissue defects in plastic surgery, the use
of PRP increases the survival of pre-adipocytes and adipocytes. Pre-adipocytes treated with
PRP showed anti-apoptotic activities and decreased the expression of molecular mediators of
cell death including Bcl-2-interacting mediator of cell death [7]. Additionally PRP can protect
human tenocytes against cell death induced by ciprofloxacin and dexamethasone [8]. Further‐
more, PRP could alleviate BMSC death under hostile conditions increasing the levels of
paracrine interactions via stimulation of PDGFR/PI K/AKT/NF-kB signaling pathway [9]. PRP
also promoted rejuvenation of aged and senescent MSC in vitro [10].
TLR receptors and DAMP-TLR activation is thought to be important in restoring homeostasis
after cell death. Recent research has added layers of complexity to our understanding of PRP,
and information about how molecular components of PRP interfere with DAMP signaling
through NF-kb illustrates the anti-inflammatory effect of PRP in several tissues [11].
3.1.2. Pattern of leukocyte infiltration
The magnitude, pattern and timing of leukocyte infiltration are better described when tissue
stress is induced by pathogens. However, in the case of sterile injuries, the extravasation of
leukocytes in response to tissue damage is less understood. Actually, it is uncertain how PRP
influences these three parameters: first, the magnitude of leukocyte infiltration, second, the
pattern, and lastly, the timing.
The way PRP influences infiltrating immune cells is important because the latter play a major
role in determining the outcome of tissue repair along with the secretory phenotype of local
cells
3.1.2.1. Polimorphonuclear cell (PMNs) infiltration
The increase in vessel permeability and chemotactic signals from the injured tissues facilitates
extravasation and movement of leukocytes within tissues by diapedesis. The use of PRP in this
stage of healing modifies several aspects, first PRP increases vessel permeability by releasing
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VEGF (also known as permeability factor, PF); in addition catecholamines such as dopamine
and noradrenaline are delivered from dense granules in addition to histamine, all with
synergistic effects in augmenting vessel permeability [12].
Polymorphonuclear cell (PMNs), including neutrophils (60-65% of the total leukocytes),
eosinophils and basophils extravasate from the blood stream and perform a graded infiltration
that reaches maximums in 12-24 h and is followed by decline, stop and apoptose. Excessive
PMNs infiltration may be detrimental for the tissue because PMNs release a wide array of
cytotoxic molecules. Granule components include several non-selective proteolytic enzymes,
cytotoxins, antimicrobial peptides; in addition to the production of reactive oxygen species
(ROS). The lifespan of neutrophils in the bloodstream is limited to hours but when they
extravasate, the presence of DAMPs’ agonists in the infiltrated tissues prolongs neutrophil
survival.
PRP may influence both the amount of neutrophil infiltration and the survival of neutrophils
in the injured tissues. In fact, PRP delivers both CCL and CXCL chemokines that attract
different leukocyte subsets. In particular, CXCL7 (very abundant in platelets) in collaboration
with NAP2 provides a strong chemotactic signal for neutrophil infiltration. In addition, PRP
releases a known chemotactic cytokine for neutrophils, CXCL8/IL8. Moreover, we have
recently shown that these chemotactic signals are reinforced and augmented by local cell
synthesis in vitro [13]. PRP can also modify the lifespan of infiltrated leukocytes by modifying
the molecular environment of the injury.
Thus, the administration of PRP would presumably modify the innate immune response,
mainly by altering the molecular environment and the chemotactic driven pattern of neutro‐
phil infiltration, the intensity and the timing. However, these effects may be dependent on the
tissue conditions and anatomical location.
3.1.2.2. Monocyte/macrophage infiltration and polarization
During the initial days subsequent to injury (from 2 h to 72 h) monocyte/macrophages
gradually infiltrate the tissue, ready to clean up apoptotic neutrophils. Indeed, macrophages
are specialized in clearance of death cells.
The expression “macrophage polarization” refers to the ability of macrophages to change their
functional phenotype in response to molecular signals they sense in their microenvironment.
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Macrophages have been categorized conventionally into pro-inflammatory M1 and tissue
repairing M2 phenotypes. In the presence of LPS or IFN-gamma macrophages are “classically”
polarized and denominated M1 macrophages. They have an inflammatory phenotype as they
express IL-1b, IL-6, IL-8 and TNF-a.
Instead, in the presence of high levels of IL-4, M2 macrophages are “alternatively” polarized
and they produce anti-inflammatory cytokines, including IL-10, IL-1Ra, CD-36, scavenger
receptor A or mannose receptor. However, growing knowledge about macrophage plasticity
indicates that M1/M2 polarization is an over-simplified view. As a matter of fact, a continuum
range of polarization states exist between the two extremes M1 and M2.
Inflammatory mechanisms are protective mechanisms that should be ideally self-limited and
lead to complete resolution returning to tissue homeostasis. Recent data indicate that M1/M2
activation states are extremely plastic to external signals and macrophages can be repolarized
from M2 to M1 states although the mechanism is unknown [14]. Resolution of inflammation
is an active process involving the biosynthesis of specialized pro-resolving mediators by M2
polarized macrophages.
Assuming that manipulation of macrophage polarization can be a tool for therapeutic
exploitation, it is imperative to gain knowledge about how PRP influences macrophages. In
fact, PRP modifies the environment and macrophages can gain distinct functions supporting
their participation in inflammation or alternatively in the resolution of inflammation. Previous
data showed that CXCL4/PF4 induces a polarization state distinct from M1 or M2 [15], and the
term M4 polarization has been proposed. This is relevant because PF4 is one of the most
abundant cytokines stored in platelets’ alpha-granules (micromolar concentrations), and is
released from platelets upon activation. However, M4 polarization has been studied in the
context of atherosclerosis, but not in tissue repair.
Therefore, further research is indispensable to establish how PRP would influence the
activation state of macrophages, and whether resolution of inflammation can be achieved by
exposing macrophages to determined molecular environments.
3.1.3. Regulation of fibrotic pathways
Fibrotic tissue is characterized by excessive type 1 collagen accumulation that hinders tissue
regeneration. The presence of myofibroblasts is central to fibrotic tissue production. They
originate from a spectrum of cellular sources, and several molecular pathways can induce the
transition of cells to myofibroblasts. In fact, myofibroblasts can describe a functional status
rather than a fixed cell phenotype. Fibrosis is predominantly controlled by TGF-b1, which is
secreted as an inactive protein associated to a latent protein. TGF-b1 enhances strongly the
synthesis of type 1 collagen by creating an autocrine loop; additionally it is an antiapoptotic
agent for myofibroblasts. TGF-b1 is abundant in PRP, stored in considerable amounts in a-
granules and secreted upon platelet activation. Additionally leukocytes secrete TGF-b1. TGF-
beta-stimulated M2-like macrophages have profibrotic activity [16]. Instead, serum amyloid
protein present in plasma has been shown to inhibit fibrosis in different models by regulating
macrophage function. Thus, PRP actions are theoretically paradoxical regarding the develop‐
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ment of fibrosis. However, clinical practitioners using PRP injections rarely report the presence
of fibrosis.
Scarring is also a key problem for axon regeneration because fibrotic tissue may block axon
growth and impair axon function.
3.2. Angiogenesis
The supply of oxygen is essential for cell metabolism and wound healing. Indeed, poor tissue
perfusion creates a hypoxic environment that impairs the healing process. Angiogenesis
involves multiple biological mechanisms including cell migration, proliferation, and differ‐
entiation.
Vascularization occurs through outgrowth of preexisting blood vessels (angiogenesis) and
involves cell migration and proliferation. Upon injury, vessels consisting of naked endothelial
cell channels have potential to sprout and branch providing nutrients and oxygen to regener‐
ating tissues. Vessel sprouting and enlargement are driven by migratory endothelial cells (EC)
called tip cells. Additional types of cells, i.e. smooth muscle cells and pericytes, are involved
in vessel stabilization. Both mechanisms, angiogenesis and arteriogenesis, involve a wide array
of cytokines and growth factors that can be supplied in physiological concentrations by PRP
administration (Table 1). Essentially, PRP cause endothelial cell proliferation and capillary
tube formation in vitro.
Alternatively to angiogenesis, new vessels can be formed through mobilization and domicil‐
iation of progenitors of endothelial cells to sites of tissue injury (vasculogenesis) or ischemic
tissues, a process mediated by VEGF and SDF-1a binding to CXCR4 receptors on EPCs.
PRP augments ischemic neovascularization presumably due to the stimulation of the three
above described mechanisms: angiogenesis, arteriogenesis and vasculogenesis. Arteriogenesis
is the main driver of restoration of blood perfusion in ischemia [17].
Indeed, the importance of coagulation factors and of platelet secretome (VEGF, TGF-b1, PDGF,
bFGF, angiopoietin) is evident for angiogenesis, not only because of their individual actions
but because of beneficial synergies between these GFs. For example, Ang-1, an EC survival
factor, stimulates capillary tube formation synergistically with VEGF. Also synergy between
both PDGF and VEGF results in the formation of a more mature vascular network than when
each factor is given alone [18]. Also the angiopoietin system contributes to vessel maintenance
growth and stabilization.
Paradoxically, platelets also provide several antiangiogenic factors necessary for vessel down-
regulation. Angiogenesis inhibitors (CXCR3 agonists) such as PF4 and TSP-1 are very abun‐
dantly stored in platelets. Additionally, angiostatin, a product of plasminogen proteolysis,
inhibits angiogenesis. Both pro- and anti-angiogenic properties have been attributed to TGF-
b1. At low doses it contributes to the angiogenic switch in part by upregulation of VEGF and
uPA, whilst at high doses contributes to the resolution of angiogenesis by inhibiting EC
proliferation and migration, promoting the reformation of the basement membrane.
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PRP- associated angiogenesis stimulators PRP-associated angiogenesis inhibitors
Vascular endothelial growth factor (VEGF)
Basic fibroblast growth factor (bFGF)
Platelet-derived growth factor (PDGF)
Epidermal growth factor (EGF)
Hepatocyte growth factor (HGF)
Insulin like growth factor 1, 2 (IGF-1, IGF-2)
Angiopoietin (ANGPT1)
Matriz metalloproteinases 2, 9 (MMP-2 and -9)
Lipoprotein A (LPA)
Sphingosine-1-phosphate (SIP)
Stromal cell derived factor (SDF-1, CXCL12)
Heparanase
Deoxyribose-1-phosphate
CD40-L
IL-8, CXCL8
CXCL12
Angiostatin
Endostatin
Platelet factor 4 (PF4)
Plasminogen activator inhibitor (PAI-1)
Transforming growth factor (TGF-beta)
Thrombospondin-1 (TSP-1)
Tissue inhibitor of metalloproteinases -1, -4
(TIMP-1,-2,-3,-4)
Fibronectin
α2-macroglobulin
Down-regulate vessel permeability Increase vessel permeability
Angiopoietin-1
Serotonin
Sphingosin-1-P
VEGF
Histamine
Noradrenaline (NE)
Dopamine (DA)
Table 1. PRP-associated positive and negative regulators of angiogenesis. Some of these molecules may have both pro-
and anti-angiogenic potential depending on the situation at the time of their release and/or the expression of cryptic
sites. Reproduced from International Journal of Clinical Rheumatology, August 2012, Vol.7, No4, Pages 397-412 with
permission of Future Medicine Ltd.[21]
As shown above, PRP provides the opportunity to therapeutically manipulate angiogenesis
by targeting multiple cell phenotypes. Crosstalk between cell types along with multiple signals
constitutes the complex system that regulates angiogenesis. Not only the activities of endo‐
thelial cells, but also of endothelial progenitors, smooth muscle cells and pericytes are
influenced by PRP signals. Pericytes, crucial for vessel stabilization, can arise from different
cell sources since they can transdifferentiate from the endothelium, a common vascular
progenitor or a mesenchymal progenitor. The association of pericytes with newly formed
vessels regulates EC proliferation, survival, migration, differentiation and vascular branching,
blood flow and vascular permeability. Pericytes have important roles in tissue repair. For
example, in skeletal muscle perycites arise from blood vessels and express NG2 proteoglycan
and alkaline phosphatase and they efficiently regenerate the muscle expressing myogenic
markers only when fully differentiated [19-20]. However, no information is yet available about
the interaction of the molecular pool released from PRP and pericytes.
Other cooperative mechanisms such as partial degradation of the ECM and basement mem‐
brane are necessary to facilitate cell migration during angiogenesis. Actually, several protease
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families released from PRP including plasminogen activators (uPA and PAI-1), and MMPs
have been characterized as having a role in the proteolytic degradation and remodeling of the
subendothelial basement membrane and the surrounding ECM. By digesting ECM proteins,
these enzymes create a path for tip cell migration. Platelets contain fibrinolytic factors and
enzymes that may regulate precisely the pericellular proteolytic environment required for the
control of cell migration and matrix remodeling. For example urokinase plasminogen (uPA)
and plasminogen activator inhibitor type I (PAI-1) proceed as modifiers of the pathway that
impact migratory events. Almost all cell types need to migrate under physiological or
pathological conditions. Clearly the binding of PAI-1 with its several targets has the potential
to influence the motile program at multiple levels. Further complexity is provided by the
presence of endogenous proteases inhibitors (TIMPs) that control the activity of proteases.
3.3. Stem/precursor cell activation and differentiation
It has been demonstrated in last years that most organs have a resident pool of somatic, tissue
specific cells. These stem cells are located in niches characterized by a typical spatial localiza‐
tion, the anchorage of stem cells to supporting cells, and the presence of typical extracellular
matrix. These cells are docked in specific microenvironments that control their survival and
self-renewal capabilities preventing them from exhaustion. In the niche, the integration of
stimulatory and inhibitory signals determines cell quiescence.
In general, these cells are mitotically quiescent. PRP contains agents able to restore mitosis in
quiescent precursor cells, consequently mitotically arrested cells are able to divide again. By
definition, these precursor stem cells are capable of self-renewal and have various potentialities
for differentiation. In general they are committed to differentiate in the local cell phenotype
and are designed to substitute dying cells during turnover, trauma or pathology. PRP
participates in mobilization of progenitor cells and proliferation but its effects in differentiation
are controversial [22].
PRP influences the number of stem cells by virtue of its mitotic effect and maintains stemness
in most settings. Actually, the effects of PRP on the differentiation of synovium derived MSCs
are negative in all three lineages and PRP alone maintains MSCs stemness [23]. Besides PRP
inhibits differentiation of adult rat tendon stem cells towards nontenocyte lineage [24]. Recent
research in skeletal muscle repair has shown that PRP maintains stemness of muscle progenitor
cells [25]. Though, PRP did not interfere with the osteogenic, chondrogenic and myogenic
differentiation in the appropriate differentiation conditions.
In many cases of traumatic injury or disease the quantity and potency of this endogenous pool
of precursor cells is insufficient to regenerate compromised tissues and migration and homing
of mesenchymal stem cells circulating in the blood stream is required.
In fact, bone marrow contains several types of stem cells including hematopoietic cells that
differentiate into mature blood cells, endothelial progenitor cells and MSCs which are
proposed to give rise to the majority of marrow stromal cell lineages including chondrocytes,
osteoblasts, fibroblasts, adipocytes, endothelial cells. Circulating MSCs in the blood stream
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can home injured tissue in response to chemoattractants released from platelets such as
SDF-1a/CXCL12.
PRP was shown to be effective in promoting the migration of MSCs. In addition PRP can
increase the number of MSC by stimulating proliferation. Actually the number of CMOs
manufacturing cells for in-human trials are taking advantage of the mitogen properties and
fetal calf serum [FCS) the typical cell culture supplement is being substituted by PRP. Several
studies showed that population cell doublings is enhanced by PRP, that is to say PRP reduces
the time needed to get a predefined cell number necessary for efficacious cell therapy [26].
3.4. Modulation of nerve repair
Peripheral nerve injury and regeneration
Peripheral nerves have the capacity to regenerate after an axonal injury. There are several kinds
of peripheral nerve damages depending on the damage of the axon and surrounding tissue.
After an injury or a breakdown, axon is able to regrow expressing repair-related molecules
and aided by Schwann cell activation, proliferation, phagocytic activity and production of
neurotrophic factors. These factors activate signaling cascades promoting synthesis of
molecules related to axonal regeneration events. In addition to producing bioactive molecules,
Schwann cells form structures called Bünger bands, which have as a function the physical
guidance of growing axons [27]. They also recruit macrophages to the injury site to remove
debris from the injury and help them supporting axon repair by secreting chemokines. As a
result, axon healing is the result of the interaction between molecular signals and cellular
events which allow proper growth of the axonal stump and consequent recovery of its
functional activity at the end of healing process.
Peripheral nerve fibers are stimulated immediately after injury and release several neuropep‐
tides into the microenvironment of the wound. Substance P, neuropeptide Y and calcitonin
gene-related peptide (CGRP) influence endothelial cells, fibroblasts and are involved in
vasoregulation and angiogenesis.
Growth factor and cytokine involvement in nerve healing
All these results have been attributed to growth factors released from platelets when activation
occurs, but an accurate function and optimal concentration have not been identified [28].
Platelets release a high number of growth factors which may have precise effects on their own,
or work synergistically depending on their concentration. Wound healing is influenced by
diverse growth factors secreted by platelet such as PDGF, TGF-β, PF4, VEFG, EGF, PDEGF,
IGF-I and others. Although these are not classically classified as neurotrophic, they have been
demonstrated to have a role in Schwann cell migration, proliferation, neuron metabolism,
synthesis of neurotrophic factors, matrix formation and myelinization and thus in axon
regeneration [29-33]. Also, platelets release other molecules which are not growth factors such
as catecholamines, histamine, serotonin, ADP, ATP and others which take part in blood vessel
formation, immune reactions both innate and adaptive, and thus in tissue regeneration [30].
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Nerve healing depends on equilibrium between Schwann cell proliferation and activation and
neurotrophic molecules which create a regenerative milieu which helps axon repair and
myelinization. Several growth factors present in PRP, such as PDGF, TGF-β1 and FGF-II, have
shown to promote Schwann cell proliferation, activation and differentiation which may
explain beneficial PRP effects shown in the previously commented studies [30, 33]. These
growth factors, for which Schwann cells and neurons have membrane receptors, trigger the
expression and subsequent synthesis of classic neurotrophic factors such as nerve growth
factor [NGF), Glial derived growth factor (GDNF), brain-derived neurotrophic factor (BDNF)
and ciliary neurotrophic factor (CTNF)[30, 32]. Also, PDGF expression has been shown to be
enhanced in neurons after a nerve injury, which may support the theory that this growth factor
has an important role in axon healing. Another growth factor present in PRP, which has been
signaled as neurotrophic is VEGF. It has been shown to be neuroprotective, to also augment
Schwann cell proliferation and axon growth [30]. IGF-I has also been pointed out as a central
promoter of nerve healing. In vitro, it has been observed that IGF enhanced neuron axonal
growth and that myelinization does not occur when IGF is removed. Also, IGF has been shown
to promote Schwann cell proliferation and migration. In vivo, IGF injections in the site of nerve
injury have been proved to ameliorate nerve healing and myelinization [28, 29,30, 31].
In the clinical arena, perineural injections of PRP induced sensorial recovery in leprosy
peripheral neuropathy [34].
4. PRP formulations and regulatory requirements
Innovative therapeutic tools appear in the horizon when basic knowledge and research
surpasses a certain threshold and is ready for translation into the clinics. PRP technologies
showed up in the late 80s, mainly based on increased knowledge about the functional role of
platelets. Platelets are cytoplasmic fragments of the megakaryocyte in the bone marrow. A
variety of molecules are stored in platelets’ granules either synthesized by their parent cell the
megakaryocyte or captured in the circulation. In PRP technologies platelets are used because
of their capability to function as vehicles for growth factors and cytokine delivery.
Initially platelets were mainly studied because of their fundamental role in hemostasia.
Allogeneic PRP, either derived from a single donor or pooled donors, has been used since the
60s as a transfusion product. In fact platelet transfusion is indicated in patients with platelet
counts below 30,000 plt/ul or below 100,000 plt/ul if they are to follow a surgical procedure.
Later in the 80s clinical researchers showed off that beyond their role in hemostasia, PRP
derived product (PDWH) were effective in the management of chronic leg ulcers [35] and were
an aid in cardiac surgery [36].
In the 90s, maxillofacial surgeons and oral implantologists introduced the clinical use of PRPs
as autologous modifications of fibrin glue. They were confounded by the effects of PRP in bone
regeneration in doing so accelerating the stability of dental implants. Of note, the anti-
inflammatory properties in soft tissues, presumably attributed to the presence of platelets in
the preparation, was another hallmark in PRP findings.
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In the new millennium, the use of PRP has been boosted not only by research in maxillofacial
surgery and oral dentistry but also by new applications in orthopedics and sports medicine.
In 2007, the term and definition of platelet rich plasma was introduce in Pubmed as a medical
subject heading (MeSH) to be used for indexing scientific articles.
However, the definition of PRP in Pubmed is out of date by several reasons. First, PRP is not
only used in surgical procedures but it is also used in the conservative management of non-
healing ulcers and as an injectable in the management of chronic pathologies such as tendi‐
nopathies or osteoarthritis. Secondly, the current definition claims that GFs in platelets
enhance tissue regeneration this is true but only up to a point. In fact, not only GFs from
platelets but also plasmatic GFs have a crucial role in repair. Besides, this definition overlooks
the hundreds of proteins released from platelets that also participate in healing. Despite all
these limitations, PRP inclusion as MeSH term has served to harbor PRP research under a
unique term.
PRPs differ from conventionally synthesized drugs in that they are products derived from
living sources. Indeed platelets are lively cells and they may experiment several temporary
transformations from preparation to local tissue delivery. The process is known as platelet
activation and involves changes in platelet morphology, aggregation, centralization of
granules, and secretion of their content to the extracellular milieu. Another peculiarity is that
PRP products are complex multi-molecular mixtures that cannot be readily characterized and
reproducibility in the composition is influenced by biological inter-individual variability.
4.1. Types of PRP products
PRP is prepared by taking a given volume of blood from a patient and processing it to separate
blood components and concentrate the platelets and optionally the leukocytes. Importantly,
the manipulation of blood in order to obtain PRP is minimal.
The nomenclature of PRP products reached a zenith of confusion at the beginning of the new
millennium. In fact, more names than products appeared and the number of commercial terms
was endless, including platelet concentrates (PC), autologous growth factors (AGF), plasma
rich in growth factors (PRGF), platelet gel (PG), platelet rich fibrin matrix (PRFM) etc... It was
evident that there were more names than PRPs to be named.
In 2009, Dohan [37] inspired the present nomenclature and classification of PRPs. Broadly
speaking PRPs were categorized as pure PRP and leukocyte and platelet rich plasmas.
Considering fibrin architecture and platelet counts we can differentiate further PRP subsets.
Different PRP devices and harvest yield in terms of platelet and leukocyte count lead to the
proposal of classification systems for PRP.
Alternatively to commercial automatic systems, PRP can be prepared in blood banks with
highly standardized procedures. In this setting, PRP is prepared from a higher volume of
blood, quality is assessed and aliquots of PRP are frozen for posterior applications. PRP
obtained in blood banks are less expensive than PRPs obtained with automatic devices.
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For blood withdrawal, many PRP protocols use anticoagulants to prevent blood from clotting.
Most kits use ACDA or sodium citrate to chelate calcium ions in doing so preventing pro‐
thrombin conversion into thrombin. Other anticoagulants (i.e. heparin, EDTA) are avoided
because they may compromise platelet stability and activation. Notwithstanding, ACDA and
sodium citrate make the plasma acidic and some protocols recommend buffering the PRP back
to a physiologic range prior to injection. Alternatively, PRP products such as leukocyte and
platelet rich fibrin (L-PRF) do not use anticoagulants and fibrin is formed during the centri‐
fugation step. Evidently, these products have a physiological pH but cannot be used as
injectable.
Importantly, PRP activation is needed to induce the secretion of granule contents i.e. platelet
secretome. This occurs spontaneously in blood but is inhibited if the blood is withdrawn in
tubes containing anticoagulants. Reversion of anticoagulants inhibition of coagulation and
platelet activation can be achieved by several procedures. One possibility is the addition of
calcium or thrombin/Ca2+ to cleave fibrinogen with subsequent polymerization of fibrin
monomers. Alternatively, physiological activation can be achieved by injecting the un-
activated PRP that once in contact with collagen and other tissue factors will get activated. The
mode of delivery of PRP has also to be taken into account, since it is a more involved process
than the delivery of a drug or a single recombinant protein. The application protocol and post-
application management involved will have a huge impact on determining whether the
potential efficacy is seen.
Device
Commercial
name
Technology FDA
approved
Total
process
time
Disposable
list Price
Increase
above
baseline
Platelet
recovery
PRP
formulations
GPS III™
(Biomet)
Floating Buoy 510(k) 15 min $700 3.2x 90% L-PRP
Angel
(Arthrex)
Computer Aided
system
510(k) 25 min $495 4.3x 76% L-PRP
ACP
(Arthrex)
Standard
Centrifugation
Thixotropic gel
510(k) 5 min $295 2.1±2x 60% Pure PRP
AutoloGel
System
(Cytomedix)
Standard
Centrifugation
510(k) 1-2 min $325 1x 78% L-PRP
GenesisCS
(Emcyte)
Direct Siphoning 510(k) 16 min $1550 10±3x
(4ml)
68±17.1% L-PRP
Pure PRP 2
(Emcyte)
Standard
Centrifugation
Pending 5.5 min N/A 8-16x 76% Pure PRP
Harvest®
SmartPrep2
Floating Shelf 510(k) 16 min $395 4x 72.0±10% L-PRP
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Device
Commercial
name
Technology FDA
approved
Total
process
time
Disposable
list Price
Increase
above
baseline
Platelet
recovery
PRP
formulations
BMAC™
Symphony II
(Depuy)
Floating shelf 510(k) 16 min $395 4x 72.0±10% L-PRP
Magellan™
(Arteriocyte)
Computer Aided
System
510(k) 17 min $350-495 5.1x 70% L-PRP
Dr PRP USA
(Rmedica-
Korea)
Standard
Centrifugation
Approved 12 min N/A N/A 97% L-PRP
Prolo 30-50
(RM Bio Co,
Ltd.)
Standard
Centrifugation
None N/A N/A 4-6x N/A L-PRP
Prolo-High
(RM Bio Co
Ltd.)
Standard
Centrifugation
None N/A N/A 5-8x N/A L-PRP
PRGF®-
Endoret®
(BTI)
Standard
Centrifugation
510(k) 28 min N/A 1-3x 70% Pure PRP
CASCADE®
Autologous
Platelet System
(MTF)
Standard
Centrifugation
Thixotropic gel
510(k) 20 min N/A 1-2x N/A Pure PRP
YCellBio PRP
YCELLBIO
MEDICAL
Standard
Centrifugation
510(k) 15 min $80 7-9X N/A L-PRP
Table 2. Main characteristics of the devices and/or kits used to prepare PRP. Modified from: http://
www.perfusion.com/perfusion/prpdevicesummary.asp
4.2. Regulatory
Regulatory requirements for PRPs are not uniform across the world. For example, in the US,
PRP is not a product instead administration of PRP is a procedure and is, therefore, not subject
to regulation by the FDA. However, the devices used to prepare PRP are regulated by the FDA
premarket approval process and have to get a 510(k) clearance.
Devices and procedures destined to prepare PRP are classified for their intended use as class
III medical devices and reach the market via premarket approval application. The product is
evaluated to ensure that the product is safe and effective and displays consistent performance
characteristics. 510(K) premarket notification exists for products that are similar to those
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already marketed usually called predicate device. In these cases 510(k) clearance is evaluated
only for substantial equivalency.
Table 1 shows devices and/or kits for PRP preparation
At the European level there is no harmonized regulatory framework for PRP therapies, and
each country has its own approach to PRP regulation within the jurisdiction of national
authorities. Devices must comply with Class II-a medical device directive 93/42/EEC. Device
approval in EU is overseen in each EU country by a governmental body called a Competent
Authority. Instead, the surgical use of PRP can be considered as an autologous graft within
the surgical procedure as regulated by Directive 2004/23/EC.
Of note, if regulatory requirements for PRP therapies were over-interpreted, unnecessary work
derived therein will increase costs and hamper the clinical use of PRP therapies. This hypo‐
thetical situation would be prejudicial for many patients since advancements in PRP science
can provide effective treatments for pathologies with substantial social and economic burden.
4.2.1. Reimbursement
Currently most insurance plans do not reimburse for PRP treatment due to the lack of data
about their efficacy. Interestingly, in the US Category III, code 0232T is used for emerging
technologies and applies for nonsurgical uses of PRP. This code allows data collection to be
used to document widespread use for FDA approval and potential reimbursement. Besides,
this code will allow the AMA (American Medical Association) to track the use of PRP, since
codes T are considered experimental they will require pre-authorization for payment. If a
physician feels that the patient would benefit from PRP injections, typically as a step to avoid
a more costly and invasive procedure preauthorization for PRP reimbursement should be
requested. Presentation of cost savings rationale can be the key to successful preauthorization.
In general managers are concerned about physician’s plans to get injured patients back to
productivity or work.
5. Translational uses of PRP biotechnology clinical relevance of PRPs
The goal of this section is not to provide an exhaustive overview of current clinical studies but
to identify and briefly describe the miscellaneous clinical applications. PRP is considered
investigational because currently, there is insufficient evidence to support the use of PRP for
all the indications included below.
The use of PRPs has extended to multiple clinical fields and novel applications are emerging
to meet varied clinical needs. The increasing use of PRPs in sports medicine, (after withdrawal
of restrictions imposed by the IOC International Olympic Committee) and PRP applications
in areas such as dentistry and plastic surgery is expected to drive the financial growth of PRPs,
that was estimated in the US market as CAGR annual growth rate of 14% from 2009 to 2016
($45m in 2009 will reach $126m in 2016) (http://www.researchviews.com/healthcare/medical/
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orthopedicdevices/Viewpoints.asp x?sector=Orthopedic%20Devices&DocID=10728). The
diffusion of PRP is attributed to the biosafety of the product due to its autologous origin.
In general, clinical uses of PRP can be categorized in two. First surgical applications, when
PRP is used in surgery as an aid to enhance repair, not only of target tissues but PRP also aims
to enhance the healing of all the adjacent tissues damaged during the procedure, and secondly
conservative uses of PRP, most often involving more than one application and used in
outpatient settings. Besides, the use of PRP associated to other medical procedures (laser
therapies, etc) offers potential to enhance such procedures. Table 3 and Table 4.
5.1. Treatment of non-healing wounds
PRP has been used to treat non-healing wounds for more than 2 decades. In fact, the topical
management of chronic leg ulcers was the first clinical application of platelets outside the blood
stream with healing purposes. Theoretically PRP or its derivatives are stimulants for non-
healing wounds; the goal is to re-activate healing. The rapid formation of granulation tissue
can prevent further deep tissue involvement and associated co-morbidities.
Complex non-healing wounds can have different etiologies including pressure ulcers,
diabetes, venous, arterial, or surgical trauma. Impaired wound healing is the major compli‐
cation that results in the development of chronic wounds often leading to amputations as often
occurs in the diabetic foot. Components of lower extremity amputations in the diabetic patient
include ulceration (85%), faulty wound healing (81%) initial minor trauma (81%), neuropathy
(61%), infection (59%) gangrene (55%) and ischemia (46%) (38]. Actually, the wound healing
society treatment guidelines for diabetic ulcers advises re-evaluation of the wound and
treatment based on failure to reach a 40% reduction of initial wound size by week 4 (39]. Cost
for amputations has been estimated to be between $ 20.000 and $ 60.000 per case. PRP is deemed
useful in this context because it may provide a way to reduce this cost burden to society.
Several RCT have provided data about the efficacy of PRP or PRP derivatives in non-healing
wounds. The initial platelet product known as PDWHF (platelet derived wound healing
factors) stimulated the formation of granulation tissue in chronic leg ulcers [40]. Later, PDWHF
of pooled donors was also examined in the treatment of diabetic ulcers (41]. In general,
concomitant pathologies such as diabetes do not hinder the therapeutic effects of PRP, and
autologous PRP is effective in the diabetic foot [42-43] or systemic sclerosis [44].
Despite several studies reporting the benefits of PRP in this setting, a recent meta-analysis of
ulcer care studies and PRP failed to show any statistically relevant difference favoring PRP for
the treatment of chronic wounds. Nevertheless, conclusions are not sound because they are
based on 9 RCTs with high or unclear risk of bias [45]. Additional evidences complementary
to RCT data can be obtained from practice based medicine and observational studies. These
data obtained in a real-world setting provide pragmatic evidences of PRP benefits.
Actually, some PRP manufacturers such as Cytomedix, AutoloGelTM have created wound
registries to evaluate the use of PRP and calculate cost savings based on mean treatment times;
this is realistic using patients in pretreatment run-in periods as their own controls during
standard wound care treatment [46].
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The reduction in treatment time should impact clinical and financial decisions. Significant
clinical outcomes indicated many previously nonresponsive wounds began actively healing
in response to PRP therapy. Cost effectiveness analysis comparing the potential economic
benefit of PRP to alternative therapies in treating non-healing diabetic foot ulcers, using an
economic model based on peer-reviewed data showed that PRP resulted in improved quality
of life and lower cost of care over 5-year period than other treatment modalities for non-healing
diabetic ulcers [47].
5.2. Maxillofacial and oral surgery
The field of PRP gained new impetus at the end of the nineties when maxillofacial surgeons
and dentists introduced PRP to augment oral reconstruction procedures. Since then a number
of protocols have been developed for different applications. These include socket filling after
molar extractions, implant surgery, PRP mixed with bone grafts during osteodistraction, and
in the treatment of mandibular tumor resection. Numerous articles describe earlier stabiliza‐
tion of dental implants when PRP is used to enhance the properties of bone grafts, and to
modulate the inflammatory status in the surrounding soft tissues.
The utility in several of these procedures seems evident. However, after meta-analyzing 24
studies addressing the use of PRP in the surgical treatment of periodontal diseases, it was
concluded that PRP exerts a positive effect only when used with graft materials for the
treatment of intrabony defects, but not in guided tissue regeneration. No significant benefit of
PRP was found for the treatment of gingival recessions [48].
In sinus augmentation surgery the combination of PRP with autologous bone graft led to
increased bone density at 6 months but not at three months [49].
The use of PRP in children is less known because they need little help for healing since young
cells and young blood has stronger healing potential and plasticity when compared to adults.
However, in the most frequent congenital facial malformation, i.e. cleft lip and palate, the use
of PRP is being investigated [50- 53]. The goal here is to reestablish the maxillofacial arch and
to close any oro-nasal communication. Besides, PRP is used in the closure of recurrent cleft
palate fistulas.
5.3. Plastic surgery and dermatology
A recent review in plastic surgery including 15 randomized controlled studies and 25 case-
controls showed that the outcomes were favorable in three main PRP indications: wound
healing, fat grafting and bone grafting [54].
PRP is used in breast reconstruction associated to fat grafts because it enhances the survival
of fat grafts that otherwise had a tendency to be resorbed by the organism. Similarly, the
outcome of plastic reconstruction using skin grafts can be improved taking advantage of the
pro-survival effects of PRP.
The use of PRP reduced recovery time in facial rejuvenation. In fact the addition of PRP to
lipofilling procedures resulted in a significant reduction in the number of days needed to
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recover before returning to work or restart social activities. Also the aesthetic outcome was
significantly better with PRP [55].
Combined treatments as fat graft, laser CO2 and PRP showed clinical benefits in the treatment
of atrophic and contractile scars [56].
PRP combined with erbium fractional laser therapy is effective for treating acne scars or acne,
at the same time PRP enhances the recovery of laser damaged skin [57].
PRP injected into the scalp is also used to manage androgenetic alopecia [58]. When the efficacy
of the interventions was examined in 64 patients, half of the patients showed a clinically
meaningful improvement [59]. PRP is also used in hair transplantation [60]. In this situation,
PRP shortens the time for hair formation.
5.4. Treatment of orthopedic problems
The use of PRP to solve clinical problems in orthopedics has increased with impetus in the
past five years the main reason can be the biosafety of the treatment and the fact that actual
strategies for management are insufficient. PRP is used in open and arthroscopic surgery and
as a conservative treatment for the management of chronic pathologies, most importantly
tendinopathies, chondropathies and osteoarthritis. Main properties are attributed to modula‐
tory effects on inflammation and angiogenesis along with reduction in pain [61-63].
Research in orthopedics encompasses a wide range of applications. In sports medicine,
physicians are more deeply engaged in conservative management of tendinopathies and
muscle injuries
Proposed clinical and surgical applications include spinal-fusion, osteoarthritis [hip and knee),
tendinopathy enhancement of healing after ACL reconstruction and muscle strains. The
challenge is to show that PRP is superior to the optimal available treatment.
5.4.1. Bone regeneration
In some applications PRP is used as a coadjuvant associated to autologous or homologous graft
and also to bone marrow graft. There is no compelling evidence to demonstrate the efficacy of
PRP alone in facilitating the union of long bones for union of tibial osteotomies or pseudoarth‐
rosis or fractures [64). An randomized study involving 21 participants compared PRP+alloge‐
neic graft versus allogeneic bone alone in patients undergoing tibial osteotomy in the medial
compartment in patients with OA [65]. There was a significant difference in the proportion of
bones that were united after one year in favor of PRP but evidence from a single trial is
insufficient to support routine interventions with PRP.
5.4.2. Lumbar fusion and intervertebral disc degeneration
Posterolateral arthrodesis in lumbar spine surgery was enhanced when PRP was combined
with cancellous bone graft as shown by densitometry in a prospective study [66]. However, a
randomized clinical study did not show any benefit when PRP is used with autologous bone
in mono-segmental posterior lumbar interbody fusion [67].
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Intervertebral disc degeneration is also common in orthopedics and current treatments are of
limited value to enhance the regenerative process. In fact some studies point out the efficacy
of PRP in reversing the degenerative trend of the intervertebral discs based on basic science
research [68]. However this application lacks translation in published reports.
5.4.3. Osteoarthritis
The efficacy of PRP has been most studied in knee osteoarthritis while few clinical data are
available about the therapeutic effects in hip OA.
There are several randomized clinical trials comparing the efficacy of PRP treatment with HA
administration. Also PRP has been compared with placebo administration. Two recent
metaanalysis [69,70] concluded that multiple PRP injections ameliorate pain and improves
function and tends to be more effective that HA administration. Patients with lower levels of
knee degeneration achieve better results than more advanced knee deterioration. Although
less investigated, PRP injections in the hip ameliorate symptomatology and function, however
the clinical level of evidence is low and more clinical studies are needed before claiming
therapeutic effects in this joint [71].
5.4.4. Tendon pathology
Most studies in tendon pathology involve guided injections of PRP. Indeed, the development
of real-time imaging techniques such ultrasonography enhances the safety and accuracy of
PRP delivery during percutaneous management. Consequently, investigation on the efficacy
of PRPs for managing chronic tendinopathies has grown in the last years and the quality of
the studies has improved considerably. Limitations of observational studies have been
overcome by level I and level 2 clinical trials. However due to tendon diversity and function,
the various PRP products and the diversity of application protocols, quantitative synthesis and
meta-analyses are difficult to perform.
Most frequent upper limb tendinopathies involve the supraspinatus and the medial and lateral
epicondyle. In these pathologies, the quality of clinical studies is high/moderate. A quantitative
synthesis evaluating the efficacy of PRP as an adjuvant in rotator cuff arthroscopy failed to
show any benefit associated to PRP. The only uncertainty in favor of PRP is that it may decrease
the proportion of retears, but this needs further confirmation [72].
Ultrasound guided injections and real-time follow-up has fueled the use of PRP in tendino‐
pathies
A recent metaanalysis examining the conservative management of tendinopathy has shown
that PRP provide some benefits in pain [61]. Moreover, subgroup analysis showed a modest
reduction of pain in epicondylitis [73]. However, major limitations for pooling data and
drawing firm conclusions comprise different outcome measurements and follow-up periods.
The most commonly treated tendons in the lower limb were Achilles, the patellar tendon and
the plantar fascia. PRP shows potential benefits in these anatomical locations, current eviden‐
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ces are encouraging but limited. The need is clear to compare PRP treatment with the most
adequate control for each condition.
5.4.5. Muscle injuries
PRP injections are used in professional athletes; the goal is to accelerate muscle healing, and
avoid relapses through true muscle regeneration, i.e. absence of scar tissue. Especially in elite
athletes the goal is to achieve rapid healing and resume competition faster than with conven‐
tional care. Although case series provide promising results, two recent randomized controlled
trials showed divergent results [74,75]. Protocols and PRP formulations were different in both
studies, thus further research is warranted.
5.5. Treatment of eye problems
5.5.1. Macular hole
Platelet concentrates were used in the 90s as an adjunct to macular hole healing. PRP is an
autologous alternative to fibrin glue with much more biological activity conferred by hundreds
of GFs and cytokines stored in alpha-granules. The efficacy of platelet concentrates was
examined in a multicenter double blind study involving 53 eyes in the experimental group
and 57 eyes in the control group. Injection of autologous platelet concentrates during macular
hole surgery improved significantly the anatomic success of the intervention but did not
influence visual acuity [76].
5.5.2. Dry eye
Autologous serum administered topically has been used to treat dry eye symptoms because
it can improve not only lubrication but also enhance lacrimal production since its composition
includes GFs important in this context such as EGF. However, after metaanalysing current
studies there were inconsistency in relation to the benefits provided by autologous serum [77].
As an alternative, PRP derivatives mainly the PRP released supernatant or the PRP lysate are
being investigated to improve dry eye conditions, administered topically. Alternatively, in
severe cases PRP is injected adjacent to the lacrimal gland [78]. Results indicate a significant
increase in lacrimal volume and patient’s self-reported improvements. PRP also enhanced
epithelial status after LASIK but did not affect the recovery of corneal sensitivity.as evaluated
in a controlled study in which the contralateral eye was used as control [79].
5.5.3. Corneal ulcers
Perforated corneal ulcers have been treated with PRP fibrin in a reduced number of patients
(N=11=. In all cases the corneal perforation was sealed after 3-5 days of stability of the mem‐
brane in the ulcer [80]. When PRP eyedrops were compared to autologous serum eyedrops in
the treatment of persistent epithelial defects PRP was more efficient than serum [81]. After
photorefractive keratectomy, the use of PRP enhanced wound healing and reduced haze
formation [82]
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In a prospective controlled study in acute ocular chemical injury PRP eyedrops as adjunct to
standard care was superior to artificial tears, autologous platelet lysate was also effective for
the treatment of refractory ocular GVDH in unresponsive patients [83].
5.5.4. Other therapeutic applications
Some anecdotic uses of PRP in urology for fistula repair [84], in the management of infantile
extravasation injury [85], and in gynecology for vaginal prolapse [86-87] have been published.
6. Challenges ahead
As PRP is eminently a translational technology, challenges must be addressed through three
interlinked angles: scientific, clinical and socioeconomic.
From the scientific aspect, evidence continues to build for the mechanisms of PRP in tissue
repair regulating the behavior of different cell types. At present we have a more complete
picture on how PRP influences healing mechanisms however, we do not know enough to
design formulations for specific medical problems. Difficulties to advance are attributed to the
lack of characterization of the host tissue. In fact, the host response to PRP administration will
drive the healing mechanisms. The host response invariably starts with activation of the
immune innate system as a result of PRP administration. Moreover, considering the local pH,
O2 levels, and cellular conditions of the host (i.e. number of dying cells apoptotic or necrotic)
is important not only in terms of GFs and cytokine stability but also to have information about
the main mechanism affected.
Clinical challenges: PRP research may eventually lead to superior therapies. The translational
imperative is making PRP formulation effective in defined indications. The challenge is to
customize PRP formulations. Essentially a single formulation cannot fulfill every need, from
treating a degenerative knee to repairing a pseudo-arthritic condition.
The modest benefits achieved with clinical trials addressing PRP efficacy should not reduce
our motivation, instead we need to understand better the underlying mechanisms so that the
most appropriate indications can be found and appropriate trials conducted to test the specific
indications. Novel approaches to clinical trial design shall recognize that the efficacy of these
therapies will be dependent upon delivery protocol as well as the PRP product itself.
Socioeconomic challenges: we should consider carefully the potential of PRPs to reduce costs
in chronic diseases. This could be achieved by the creation of proper registries and economic
models considering the costs generated in pre-treatment run-in periods. In patients with
recalcitrant pathologies, candidates to surgical interventions, economical algorithms will help
to estimate savings attributable to surgical and post-surgical costs relative to the conservative
management.
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Cardiac surgery Coronary artery bypass graft surgery*Aorta surgery*
Plastic surgery
Breast reconstruction**
Infected high-energy soft tissue injuries*
Skin grafts**
Fat grafts***
Pilodinal sinus abscesses*
Pediatric surgery Alveoloplasty of cleft palate*Extravasation injury (premature infants)*
Maxillofacial and oral surgery
Molar extractions***
Implant surgery***
Osteodistraction**
Periodontal disease**
Mandibular tumor resection**
Sinus lift**
Urology Uretracutaneous fistula repair *Vesicovaginal fistula*
Gynecology Vaginal prolapse*
Orthopedics and Arthroscopic surgery
Non-union (aseptic pseudo-arthrosis)*
Tendon surgery*
Morton neuroma*
Peripheral nerve regeneration*
ACL reconstruction***
Rotator cuff surgery***
Lumbar interbody fusion*
Tibial osteotomy*
Hip conditions (sacroiliac joint dysfunction)*
*** Broadly used, that is RCTs, several clinical evidences and different levels of evidence
** Moderate use, case series and at least one controlled study
* Anecdotic use, case series or an isolated prospective cohort
Table 3. Miscellaneous applications of PRPs in open surgery
Eye disease
Macular hole**
Restoration of human lacrimal function (dry eye)**
Corneal ulcers and lesions **
Chemical acute wounds
Neurotrophic wounds
epithelial
Nerve regeneration after LASIK*
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Refractory ocular GVDH*
Cardiology Complications of sternotomy**Severe deep sternal wound infection**
Dermatology
Non-healing ulcers***
Diabetic ulcer
Neurogenic
Arterial
traumatic
Pressure ulcers
Vascular ulcers
Treatment of striae distensae*
Androgenetic alopecia*
Peripheral neuropathy*
Sports Medicine and Orthopedics
Chondropathy and Osteoarthritis***
Tendinopathies***
Muscle injuries**
Ligament injuries*
Fasciitis plantar**
Recalcitrant hindfoot and ankle disease**
Per-cutaneous non-unions*
Table 4. Conservative clinical applications of PRP therapies
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